Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Johnson & Johnson (JNJ) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDrug Manufacturers - GeneralJNJ

Closing price · Nov 19, 2026 $267.11 -2.0% on the day · +34.9% over 12 months 52-week range $196.79 – $285.75
Get JNJ alerts
Open-market purchases1 insider$258K · last 12 months
Insiders selling10last 12 months
Reported sales$154M0 of 30 recent sales pre-planned (10b5-1)
In 15 seconds

Some insider buying ($258K), but sales were much larger ($154M) over the same 12 months.

Past insider buys here: 1 of 1 beat the S&P 500 over the next 90 days (small sample). See each one ↓

Label: Net selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Jan 13, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Elizabeth Forminard, General Counsel sold 13,072 shares at $284.39 ($3.7M).

Trade date
Nov 12, 2026
Disclosed to the SEC
Nov 13, 2026
Type
Sale (code S)

Read the original SEC filing ↗All JNJ insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

JNJ insider transactions (Form 4)

Open-market purchases and sales. 115 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 13SEC Elizabeth ForminardGeneral Counsel Sell 13,07216,994 held (−43%) $284.39 $3.7M -6.1% —
Sep 4SEC Timothy SchmidChair Sell 22,52725,447 held (−47%) $274.74 $6.2M -2.8% —
Sep 4SEC Timothy SchmidChair Sell 11,07025,447 held (−30%) $274.74 $3.0M -2.8% —
Aug 18SEC Jennifer L. TaubertEvp, Wwc. Innovative Medicine Sell 15,000194,451 held (−7%) $263.36 $4.0M +1.4% —
Aug 14SEC Joaquin DuatoCEO, Chair Sell 102,315275,967 held (−27%) $261.00 $26.7M +2.3% —
Aug 14SEC Joaquin DuatoCEO, Chair Sell 20,976378,282 held (−5%) $262.00 $5.5M +2.0% —
Aug 7SEC Joaquin DuatoCEO, Chair Sell 41,957282,490 held (−13%) $258.06 $10.8M +3.5% —
Aug 7SEC Elizabeth ForminardGeneral Counsel Sell 9,34423,568 held (−28%) $257.75 $2.4M +3.6% —
Aug 7SEC Joaquin DuatoCEO, Chair Sell 6,523275,967 held (−2%) $258.74 $1.7M +3.2% —
Aug 7SEC Elizabeth ForminardGeneral Counsel Sell 6,57416,994 held (−28%) $255.93 $1.7M +4.4% —
Jul 21SEC Vanessa BroadhurstEvp, Global Corp Affairs Sell 23,05423,003 held (−50%) $251.27 $5.8M +6.3% —
Jun 12SEC Kathryn E. WengelEvp, Chief To And Risk Officer Sell 10,000114,288 held (−8%) $241.15 $2.4M +10.8% —
Mar 3SEC Robert J. DeckerVp Corporate Controller Sell 4,07523,682 held (−15%) $247.87 $1.0M +7.8% —
Feb 23SEC Timothy SchmidChair Sell 1,32225,447 held (−5%) $245.66 $325K +8.7% —
Feb 18SEC Joseph J. WolkCFO Sell 33,38638,961 held (−46%) $242.75 $8.1M +10.0% —
Feb 18SEC John C. ReedEvp, Innovative Medicine, R&D Sell 29,92712,941 held (−70%) $243.00 $7.3M +9.9% —
Feb 18SEC Joseph J. WolkCFO Sell 24,96114,000 held (−64%) $242.68 $6.1M +10.1% —
Feb 18SEC James D. SwansonEvp, Cio Sell 22,19125,020 held (−47%) $243.71 $5.4M +9.6% —
Feb 18SEC John C. ReedEvp, Innovative Medicine, R&D Sell 21,72112,941 held (−63%) $243.00 $5.3M +9.9% —
Feb 18SEC James D. SwansonEvp, Cio Sell 20,52125,698 held (−44%) $242.70 $5.0M +10.1% —
Feb 18SEC James D. SwansonEvp, Cio Sell 19,36825,020 held (−44%) $243.76 $4.7M +9.6% —
Feb 18SEC Joseph J. WolkCFO Sell 19,24138,961 held (−33%) $242.99 $4.7M +9.9% —
Feb 18SEC Timothy SchmidChair Sell 13,62526,769 held (−34%) $244.20 $3.3M +9.4% —
Feb 18SEC Joseph J. WolkCFO Sell 12,06638,961 held (−24%) $242.87 $2.9M +10.0% —
Feb 18SEC Timothy SchmidChair Sell 8,99826,769 held (−25%) $244.53 $2.2M +9.2% —
Feb 18SEC Vanessa BroadhurstEvp, Global Corp Affairs Sell 6,19723,003 held (−21%) $243.39 $1.5M +9.7% —
Feb 18SEC John C. ReedEvp, Innovative Medicine, R&D Sell 2,28310,658 held (−18%) $243.00 $555K +9.9% —
Jan 28SEC Joaquin DuatoCEO, Chair Sell 51,21879,634 held (−39%) $220.99 $11.3M +20.9% —
Jan 28SEC Joaquin DuatoCEO, Chair Sell 48,78230,852 held (−61%) $221.48 $10.8M +20.6% —
Dec 1SEC John G. MorikisDirectorFirst buyStake +209% Buy 1,2501,849 held (+209%) $206.15 $258K +29.6% —
Oct 20SEC John C. ReedEvp, Innovative Medicine, R&D Sell 21,72110,658 held (−67%) $192.71 $4.2M +38.6% —
Historical context

Similar past setups: not applicable. There aren't enough comparable past cases for JNJ's latest buying to report odds. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with JNJ in the Research Lab

Pre-set to JNJ's latest insider buy of $10K or more (Dec 1, 2025: John G. Morikis, $258K). Tap to change anything.

All tools →

Share price and insider trades

JNJ closeInsider buyInsider sale
150200250300DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-21EEarnings release filed 2026-04-14EEarnings release filed 2026-07-15EEarnings release filed 2026-10-13Bought $257,688 on 2025-11-26 · John G. MorikisSold $324,763 on 2026-02-20 · Timothy SchmidSold $1,010,070 on 2026-02-27 · Robert J. DeckerSold $2,411,500 on 2026-06-11 · Kathryn E. WengelSold $3,717,546 on 2026-11-12 · Elizabeth ForminardSold $3,950,400 on 2026-08-17 · Jennifer L. TaubertSold $4,090,960 on 2026-08-06 · Elizabeth ForminardSold $5,527,506 on 2026-02-18 · Timothy SchmidSold $5,792,686 on 2026-07-20 · Vanessa BroadhurstSold $9,230,440 on 2026-09-02 · Timothy SchmidSold $10,129,312 on 2026-02-13 · James D. SwansonSold $12,515,010 on 2026-08-05 · Joaquin DuatoSold $22,122,893 on 2026-01-26 · Joaquin DuatoSold $32,199,927 on 2026-08-13 · Joaquin DuatoSold $41,361,795 on 2026-02-17 · James D. Swanson, John C. Reed, Joseph J. Wolk, Vanessa Broadhurst
Bought, 12 months$258K
Sold, 12 months$154M
Insiders buying1
Insiders selling10

Johnson & Johnson insider trading at a glance (Nov 20, 2026): in the past 12 months, 1 insider bought $258K and 10 sold $154M of JNJ stock on the open market; P/E 43.1 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

JNJ insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $258K bought (1 trades)$258KQ4 2025: $4.2M sold (1 trades)Q4 2025Q1 2026: $80.5M sold (17 trades)Q1 2026Q2 2026: $2.4M sold (1 trades)Q2 2026Q3 2026: $67.8M sold (10 trades)Q3 2026Q4 2026: $3.7M sold (1 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$3.7M1
Q3 2026—0$67.8M10
Q2 2026—0$2.4M1
Q1 2026—0$80.5M17
Q4 2025$258K1$4.2M1

Valuation, profit and volume

P/E (trailing)43.1Sector median 25.0
Market value$683.12BDrug Manufacturers - General
Profit margin16.2%Revenue growth +5.9%
Volume vs. 50-day1.0×Last 5 sessions
Insiders' paper profit+$76KOn all tracked purchases +29.6%

Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 1 Johnson & Johnson insider reported open-market purchases totaling $258K, while 10 insiders reported sales totaling $154M. 0 of 30 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

JNJ earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 13, 2026 -2.8% None -3.7%S&P -1.1% +12.5%
Jul 15, 2026 -1.8% None -1.5%S&P -0.1% +4.2%
Apr 14, 2026 -1.0% None +0.3%S&P +2.0% -5.0%
Jan 21, 2026 +6.8% None +0.1%S&P +1.7% +11.0%
Oct 14, 2025 +6.2% None +0.1%S&P +0.3% +2.5%
Jul 16, 2025 +1.6% None +5.0%S&P +0.9% +8.4%
Apr 15, 2025 -5.7% None -0.3%S&P -2.5% -1.7%
Jan 22, 2025 +3.1% None -1.0%S&P +1.1% +11.6%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

JNJ short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 46% of volume sold short2026-08-27: 46% of volume sold short2026-08-28: 51% of volume sold short2026-08-31: 51% of volume sold short2026-09-01: 43% of volume sold short2026-09-02: 52% of volume sold short2026-09-03: 51% of volume sold short2026-09-04: 50% of volume sold short2026-09-08: 40% of volume sold short2026-09-09: 52% of volume sold short2026-09-10: 53% of volume sold short2026-09-11: 57% of volume sold short2026-09-14: 51% of volume sold short2026-09-15: 46% of volume sold short2026-09-16: 57% of volume sold short2026-09-17: 54% of volume sold short2026-09-18: 67% of volume sold short2026-09-21: 49% of volume sold short2026-09-22: 59% of volume sold short2026-09-23: 59% of volume sold short2026-09-24: 48% of volume sold short2026-09-25: 60% of volume sold short2026-09-28: 55% of volume sold short2026-09-29: 41% of volume sold short2026-09-30: 55% of volume sold short2026-10-01: 36% of volume sold short2026-10-02: 49% of volume sold short2026-10-05: 40% of volume sold short2026-10-06: 34% of volume sold short2026-10-07: 31% of volume sold short2026-10-08: 33% of volume sold short2026-10-09: 31% of volume sold short2026-10-12: 44% of volume sold short2026-10-13: 48% of volume sold short2026-10-14: 32% of volume sold short2026-10-15: 28% of volume sold short2026-10-16: 24% of volume sold short2026-10-19: 42% of volume sold short2026-10-20: 32% of volume sold short2026-10-21: 24% of volume sold short2026-10-22: 35% of volume sold short2026-10-23: 34% of volume sold short2026-10-26: 34% of volume sold short2026-10-27: 44% of volume sold short2026-10-28: 30% of volume sold short2026-10-29: 33% of volume sold short2026-10-30: 23% of volume sold short2026-11-02: 26% of volume sold short2026-11-03: 27% of volume sold short2026-11-04: 22% of volume sold short2026-11-05: 34% of volume sold short2026-11-06: 37% of volume sold short2026-11-09: 42% of volume sold short2026-11-10: 20% of volume sold short2026-11-11: 26% of volume sold short2026-11-12: 46% of volume sold short2026-11-13: 46% of volume sold short2026-11-16: 37% of volume sold short2026-11-17: 25% of volume sold short2026-11-18: 42% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 42%20-day average: 32%Prior 2 months: 45%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded JNJ

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
John BoozmanSenate Sold $1,001 - $15,000 Aug 20, 2026Sep 11, 2026 +0.4%
Thomas H TubervilleSenate Sold $15,001 - $50,000 Oct 29, 2024Aug 5, 2026 +76.1%
Thomas H TubervilleSenate Sold $15,001 - $50,000 Oct 29, 2024Aug 5, 2026 +76.1%
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 30, 2026Jul 21, 2026 +11.3%
Alan ArmstrongSenate Bought $15,001 - $50,000 Mar 27, 2026Jul 21, 2026 +12.3%
John BoozmanSenate Sold $1,001 - $15,000 Mar 19, 2026Apr 14, 2026 +13.6%

What happened after JNJ insiders bought

Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.

Across all stocks →
FiledInsiderBought7 days30 days90 days
Dec 1, 2025John G. MorikisDirector$258K -1.8%-2.3% vs S&P+0.8%+0.2% vs S&P+21.7%+20.5% vs S&P

Insiders at Johnson & Johnson

InsiderBoughtSoldLast filingPast buys beat S&PScore
Joaquin DuatoCEO, Chair — $66.8M Aug 14, 2026 — —
Joseph J. WolkCFO — $21.8M Feb 18, 2026 — —
John C. ReedEvp, Innovative Medicine, R&D — $17.3M May 4, 2026 — —
James D. SwansonEvp, Cio — $15.1M Feb 18, 2026 — —
Timothy SchmidChair — $15.1M Sep 4, 2026 — —
Elizabeth ForminardGeneral Counsel — $7.8M Nov 13, 2026 — —
Vanessa BroadhurstEvp, Global Corp Affairs — $7.3M Jul 21, 2026 — —
Jennifer L. TaubertEvp, Wwc. Innovative Medicine — $4.0M Aug 18, 2026 — —
Kathryn E. WengelEvp, Chief To And Risk Officer — $2.4M Jun 12, 2026 — —
Robert J. DeckerVp Corporate Controller — $1.0M Mar 3, 2026 — —
John G. MorikisDirector $258K — Dec 1, 2025 — —
Kristen MulhollandEvp, Chief Hr Officer — — Feb 18, 2026 — —

Board links: companies that share insiders with JNJ

Directors and executives who filed Form 4s for JNJ and another company in the last 12 months.

See the map →
  • GISGeneral Mills John G. Morikis Director here · Director at GIS · latest filing Oct 1, 2026
  • LHLabcorp Kathryn E. Wengel Evp, Chief To And Risk Officer here · Director at LH · latest filing Jun 12, 2026
  • PRUPrudential Financial Joseph J. Wolk CFO here · Director at PRU · latest filing Feb 18, 2026
  • ZTSZoetis Vanessa Broadhurst Evp, Global Corp Affairs here · Director at ZTS · latest filing Jul 21, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

JNJ stock: common questions

Are Johnson & Johnson insiders buying JNJ stock?

In the past 12 months, 1 insider reported open-market purchases of JNJ worth $258K. The latest was Director John G Morikis bought $258K of JNJ at $206.15 — first open-market purchase in our records; raises the stake by 209%.

Are Johnson & Johnson insiders selling JNJ stock?

10 insiders reported sales worth $154M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is JNJ's P/E ratio?

JNJ trades at about 43.1 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is JNJ's 52-week range?

Over the past year JNJ has traded between $196.79 and $285.75. It last closed at $267.11 on Nov 19, 2026.